Physician profile
Pablo E Splenser
NPI 1154523231
$1,548.95
in general payments reported to CMS, 2019-2025
21 companies · $23.72 in 2025
The $23.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $517 · 2021: $243 · 2023: $114 · 2025: $23.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $114 · Food and Beverage: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $113.62 |
| Food and Beverage | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $376.00 | 2019-2021 | |
| Pfizer INC. | $247.02 | 2019-2021 | |
| Novo Nordisk INC | $117.17 | 2020-2021 | |
| Astellas Pharma US INC | $107.65 | 2019-2023 | |
| Amgen INC. | $101.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $100.96 | 2019-2021 | |
| Allergan, INC. | $97.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.80 | 2019-2021 | |
| Glaxosmithkline, LLC. | $55.28 | 2019 | |
| Lilly USA, LLC | $50.98 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $43.70 | 2019 | |
| Merck Sharp & Dohme LLC | $36.10 | 2019-2020 | |
| Stryker Corporation | $23.72 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $21.03 | 2020 | |
| Pacira Therapeutics, INC. | $20.27 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Abbott Laboratories | $18.58 | 2021 | |
| Eisai INC. | $15.61 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Splenser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.